March, 2023

No. 108 (3)

2021 CiteScore: 11.8 2021 Impact Factor: 11.04 Submission > Acceptance: 49 days



Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous disease entity that encompasses nearly 30 distinct subtypes, most with an aggressive behavior. Several novel agents have been approved for relapsed/refractory (R/R) PTCL, although responses to these agents are generally not durable. Rai and colleagues present results from a multicenter, phase IIb study aimed at investigating the efficacy and safety of tucidinostat, an orally available, novel benzamide class of histone deacetylase, in patients with R/R PTCL. They show that tucidinostat is a promising new therapeutic option in patients with R/R PTCL.

Shinya Rai et al.


Dysfunctional subsets of CD39+ T cells, distinct from PD-1+, driven by leukemic extracellular vesicles in myeloid leukemias

Exhausted or dysfunctional CD4+ and CD8+ T cells, with impaired effector function and immune killing of cancer cells, are present in the immune tumor microenvironment. Therefore, the identification of novel subsets of exhausted T cells, characterized by the expression of targetable markers, could facilitate the development of new therapies. With their study Swatler and colleagues demonstrate the emergence of dysfunctional CD39+ T cells in the peripheral blood of patients with chronic and acute myeloid leukemias, due to the influence of leukemic extracellular vesicles.

Julian Swatler et al.


Enhancing regulatory T-cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia

Many studies have shown that Treg, as immunosuppressive T cells, are defective in patients with primary immune thrombocytopenia (ITP). High mobility group box 1 (HMGB1) protein, a non-histone nuclear protein, is associated with an imbalance of Treg/Th17 cells and is involved in the pathogenesis of ITP. Wang and colleagues demonstrated that 18β-glycyrrhetinic acid, a natural inhibitor of HMGB1, has the potential to restore immune balance in ITP via inhibition of HMGB1 signaling.

Haoyi Wang et al.


Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma

A small subset of cases of high-grade B-cell lymphoma (HGBL) shows a blastoid morphology and the distinction of this blastoid HGBL from CD34 negative B-acute lymphoblastic leukemia/lymphoma can be very challenging. Qiu and colleagues developed a three-point immunohistochemically focused scoring system to aid in the differential diagnosis. They also performed RNA-sequencing-based whole transcriptome profiling in order to validate their scoring system and understand the underlying gene expression signatures associated with blastoid HGBL.

Lianqun Qiu et al.